酒精使用障碍治疗对肝硬化患者临床结局的影响
该回顾性队列研究纳入2011至2015年间在退伍军人健康管理局就诊、新诊断酒精使用障碍(AUD)的肝硬化退伍军人,评估AUD治疗模式及其与临床结局的关系。在35682例患者中,仅14%在诊断后180天内接受AUD治疗;调整分析显示治疗与肝失代偿风险降低及长期全因死亡率降低显著相关。
要点
- 肝硬化合并AUD患者中仅14%在6个月内接受行为或药物治疗。
- AUD治疗与肝失代偿风险显著降低相关(6.5% vs 11.6%,AOR 0.63)。
- AUD治疗与长期全因死亡率显著降低相关(51% vs 58%,AOR 0.87)。
核心结论
- 多数肝硬化合并AUD的退伍军人未在6个月内接受AUD治疗。
- AUD治疗与肝失代偿和长期全因死亡率降低显著相关。
研究设计与样本
- 回顾性队列研究,纳入93612例肝硬化退伍军人中35682例新诊断AUD者。
- 排除2671例既往有AUD诊断且近期接受治疗者。
主要发现
- 180天内5088例(14%)接受AUD治疗,其中4461例(12%)仅行为治疗,159例(0.4%)仅药物治疗,468例(1%)联合治疗。
- 肝失代偿发生率治疗组6.5% vs 未治疗组11.6%,AOR 0.63(95%CI 0.52-0.76)。
- 短期全因死亡率2.6% vs 3.9%,AOR 0.79(95%CI 0.57-1.08),无统计学意义。
- 长期全因死亡率51% vs 58%,AOR 0.87(95%CI 0.80-0.96)。
临床怎么用
- 对肝硬化合并AUD患者应主动评估并提供行为或药物治疗。
- AUD治疗可能降低肝失代偿和长期死亡风险,应纳入综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Despite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis. APPROACH AND RESULTS: This retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96). CONCLUSIONS: Most Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence-based AUD treatments to patients with coexisting AUD and cirrhosis.
引用
- Rogal S, Youk A, Zhang H, et al. Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. Hepatology. 2020. PMID: 31758811. doi:10.1002/hep.31042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。